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Chagas disease results from infection with the trypanosomatid parasite Trypanosoma 
cruzi. Progress in developing new drugs has been hampered by the long term and 
complex nature of the condition and by our limited understanding of parasite biology. 
Technical difficulties in assessing the parasite burden during the chronic stage of 
infection have also proved to be a particular challenge. In this context, the 
development of non-invasive, highly sensitive bioluminescence imaging procedures, 
based on parasites that express a red-shifted luciferase, has greatly enhanced our 
ability to monitor infections in experimental models. Applications of this methodology 
have led to new insights into tissue tropism and infection dynamics, and have been a 
major driver in drug development. The system has been further modified by the 
generation of parasite reporter lines that express bioluminescent:fluorescent fusion 
proteins, an advance that has allowed chronic infections in mice to be examined at a 
cellular level. By exploiting bioluminescence to identify the rare sites of tissue infection, 
and fluorescence to detect T. cruzi at the level of individual host cells in histological 
sections, it has been possible to investigate the replication and differentiation status 
of parasites in vivo and to examine the cellular environment of infection foci. In 
combination, these data are providing a framework for the detailed dissection of 









The insect-transmitted protozoan parasite Trypanosoma cruzi can invade and 
replicate in most mammalian cell types. In humans, the infection is characterised by 
an initial acute stage, which can last 6-8 weeks. During this period, parasites are widely 
disseminated in organs and tissues, and readily detectable in the bloodstream. The 
infection then transitions to a chronic phase that can lead to serious pathology, 
including cardiomyopathy and/or digestive tract megasyndromes, although typically, 
symptoms take many years to develop. The drugs currently used to treat T. cruzi 
infections, benznidazole and nifurtimox, can have toxic side effects, are non-curative 
in a significant number of cases [1, 2], and both require to be activated within 
trypanosomes by the same mitochondrial-localised nitroreductase (TcNTR-1) [3, 4]. 
Parasites are difficult to detect during the long asymptomatic chronic stage, and their 
specific location(s) are not well defined. As a result, it is unclear why infections can 
have such severe consequences, and why only a minority of individuals develop 
pathology (about one-third of those infected). In addition, difficulties in routinely 
monitoring the parasite burden has significantly complicated the design and 
assessment of clinical trials to test new drugs or treatment regimens.         
 
Research on Chagas disease in humans is confounded by the decades long timescale 
associated with pathology, the diversity of symptomatic outcomes, and the lack of 
accurate methodology to assess parasitological cure. Consequently, experiments 
using predictive experimental models have taken on a central role in research, ranging 
from studies on disease pathogenesis to drug development. Here, we outline recent 
progress in optimising highly sensitive imaging procedures applicable to murine 
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models of Chagas disease. These approaches, which are based on parasite strains 
that express bioluminescent:fluorescent chimeric reporters, represent a valuable 
addition to the tools available for research on this debilitating infection. 
 
Monitoring murine T. cruzi infections using red-shifted bioluminescence 
reporters 
In vivo bioluminescence imaging is a widely used procedure in infectious disease 
research [5-8]. As a pre-requisite, it requires genetic modification of the corresponding 
pathogen to express a light-emitting enzyme, such as firefly luciferase. In the presence 
of molecular oxygen and ATP, this enzyme catalyses the reduction of luciferin resulting 
in the emission of yellow-green light (wavelength ~560 nm). Bioluminescence imaging 
of infected mice can then be used to generate a whole-body heat map that allows the 
location and relative burden of the pathogen load to be inferred (Figure 1A, as 
example). Despite being a major step forward, the sensitivity of the procedure, when 
wild-type firefly luciferase is used as the reporter protein, is limited by constraints on 
the tissue penetration of visible light at wavelengths of less than 600 nm. There are 
two major factors that cause this, light scattering and absorbance. Rayleigh scattering 
is greater at shorter wavelengths than at longer wavelengths, and haemoglobin is the 
major chromophore in tissue, and responsible for the absorbance of non-red light. To 
mitigate these issues, genetically modified red-shifted luciferases have been 
engineered to emit light at 617 nm [9], and targeted to the ribosomal locus of T. cruzi 
to ensure stable, high-level expression [10]. In combination, these manipulations have 
allowed chronic parasite infections to be monitored with unprecedented sensitivity, for 




In addition to numerous drug screening (Figure 1B) and vaccine assessment 
applications [13-17], this imaging model has provided several new insights into T. cruzi 
infections. It has been used to demonstrate that chronic infections are highly dynamic, 
with visible bioluminescence foci appearing and disappearing over a period of hours 
[11]. It has shown that infections are pantropic during the acute stage, with widespread 
dissemination throughout the viscera, skeletal muscle and skin. In contrast, during the 
chronic stage, when the infection burden has been reduced by up to 3 orders of 
magnitude, it has revealed that parasites are restricted to considerably fewer sites 
[11]. In BALB/c mice infected with T. cruzi CL Brener (TcVI lineage), parasites are 
located predominantly in reservoir sites in the colon and/or stomach, with infections of 
other organs and tissues being sporadic (Figure 1C). For example, cardiac infection 
was observed in only 10% of the mice examined, although infections of the skin and 
mesentery tissue are more common. This tissue distribution profile is independent of 
the route of infection (i.p., s.c., i.v. or oral) [11, 17]. Persistent gastro-intestinal (GI) 
tract localisation of T. cruzi was also observed during chronic infections in other 
mouse:parasite strain combinations, although in some mouse models, parasites were 
also more widely disseminated [12]. For example, in C3H mice infected with the JR 
strain of T. cruzi (TcI lineage), parasites are more frequently detected in skeletal 
muscle and the heart, although the level and extent of infection is low compared to the 
acute stage. Bioluminescence imaging has been used to show that parasite tropism 
during chronic stage murine infections is controlled by the effectiveness, or otherwise, 
of tissue-specific immune responses. Immunosuppression of infected mice with 
cyclophosphamide promotes the expansion of parasites within the GI niche (mainly 
the stomach and proximal region of the colon) over the first 6-9 days of treatment [12]. 
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This is then followed by widespread dissemination of the infection to other organs and 
tissues, to produce an infection profile more similar to that in the acute stage, when 
the adaptive immune response has yet to be induced.  
 
In mice with chronic Chagas disease, heart pathology can develop in the absence of 
persistent cardiac infection [11]. It has also been observed that higher levels of cardiac 
fibrosis occur in mouse strains where parasites have a wider tissue distribution during 
the chronic stage [12, 18]. These findings suggested a model that might explain 
chagasic pathology, in which periodic trafficking of parasites, or parasite infected cells, 
from immune-tolerant reservoirs, could lead to recurrent low-level infections at other 
sites. In organs such as the heart, these intermittent infection foci would initiate a rapid 
inflammatory immune response targeted at T. cruzi infected cells. The cumulative 
effects of these continuous rounds of local re-infection and parasite elimination over 
long periods could then lead to collateral tissue damage and fibrosis [19, 20]. This 
hypothesis has raised a number of questions, the answers to which are central to a 
fuller understanding of Chagas disease pathogenesis. For example, what is the 
immunological context of persistent infection foci during the asymptomatic chronic 
stage? What are the determining factors that allow some tissue sites to act as long-
term reservoirs of infection? Does parasite dormancy [21] have a role in immune 
evasion and/or reduced drug sensitivity? Investigating these and other questions 
related to disease pathology has been limited by technical challenges in locating, 
imaging and assessing infection foci at a cellular level during the chronic stage. Below, 
we describe how modification of the bioluminescence imaging procedures has 




Combining bioluminescence and fluorescence allows the routine detection of 
intracellular parasites in infected mice 
As outlined above, bioluminescence imaging can be exploited to monitor T. cruzi 
infections in experimental animal models, and can be adapted to assess the tissue 
and organ distribution of parasites at different stages of the disease, and to assess 
drug efficacy (Figure 1B). However, because light emission requires ATP and luciferin, 
bioluminescence imaging cannot be applied to histological sections, a crucial method 
for studying in vivo host:parasite interactions at a cellular level. Furthermore, during 
the chronic stage, the parasite burden is so low, that even with bioluminescence-
guided excision, it is extremely difficult to detect and image infected cells in tissue 
sections. One technical advance that has overcome many of these problems is the 
generation of bioluminescent parasite lines that co-express a fluorescent reporter. This 
approach is applicable because fluorescence is an intrinsic property of such proteins, 
and one that survives the processing steps necessary to prepare tissue sections for 
microscopy. To maintain stable co-expression in these parasites, it was deemed 
necessary to ensure close linkage of the bioluminescent and fluorescent genes [22], 
since murine infection experiments can last for up to 18 months, and during this period 
parasites are not under selective pressure to maintain expression of both reporters. 
The mNeonGreen protein gene was therefore integrated into the same ribosomal 
locus as the red-shifted luciferase sequence, to create a fusion gene that expressed 
a chimeric bioluminescent:fluorescent protein, with the reporters separated by a short 
linker peptide (Figure 2A). This configuration did not perturb the bioluminescent or 
fluorescent properties of the expressed protein, and the infectivity of the parasite was 
unaltered [22]. Bioluminescent tissue foci revealed by ex vivo imaging (Figure 2B), can 
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be excised, fixed, embedded in paraffin, and sections examined by confocal laser 
scanning microscopy (Figure 2C). Using this approach, it was possible for the first 
time, to visualise on a regular basis, intracellular parasites in tissue from chronically 
infected mice. At this stage of the life-cycle, when T. cruzi is restricted to a limited 
number of locations, it was feasible to locate and image infected cells, even when 
parasite numbers were extremely small, with resolution down to the level of single 
amastigotes. Furthermore, using antibody co-staining (such as the neuron-specific 
marker in Figure 2C), it is also feasible to identify the nature of infected cells and to 
place the infection in its physiological context. A second parasite line has also been 
generated in which the fluorescent component of the fusion protein was switched to 
encode an mScarlet sequence [22], opening the way to explore co-infections in fine 
detail, including in vivo drug efficacy. 
 
In the acute stage, as expected from the bioluminescence profile, infections were 
readily detectable by fluorescence in all tissue types examined, even when host cells 
contained single amastigotes (Figure 3A). Co-staining with tissue specific markers 
allows infection foci and their cellular environment to be imaged in detail (Figure 3B). 
In addition, differentiating intracellular parasites can be visualised in situ (Figure 3C), 
indicating that fusion protein levels in different stages of the life-cycle are sufficient to 
permit detection. Therefore, bioluminescence:fluorescence imaging provides a 
framework for investigating the interplay between T. cruzi replication and 
differentiation in vivo, and for examining the impact of host cell type, tissue location, 




Insights into parasite biology facilitated by bioluminescence:fluorescence 
imaging 
TUNEL assays (terminal deoxynucleotidyl transferase dUTP nick end labelling) [23] 
and 5-ethynyl-2’-deoxyuridine (EdU) incorporation [24], in combination with the in vivo 
imaging procedures outlined above, provide new approaches for exploring intracellular 
T. cruzi replication and other aspects of infection biology. In trypanosomes, the former 
can be used to assess mitochondrial DNA (kinetoplast DNA - kDNA) replication [25]. 
Terminal uridylyl transferase adds fluorescent pyrimidine nucleoside analogues to the 
transient free 3’-hydroxyl groups that are formed at nicks in newly synthesised strands 
during replication of the minicircle network. With EdU, replication in vivo can be 
monitored by incorporation of this nucleoside analogue into the parasite nuclear and 
mitochondrial genomes during DNA synthesis, a process that is detectable by direct 
fluorescent labelling using copper-catalysed click-chemistry. Both of these 
approaches have independently demonstrated that parasite replication within 
individual infected cells is asynchronous in vivo [25, 26].  
 
TUNEL positivity in trypanosomes is an early indicator that the cell division process 
has begun. Initially, kDNA replication can be visualised by staining of the “replication 
factories” at antipodal sites on each side of the minicircle network (Figure 4A) [22, 26]. 
Then, as replication of the mitochondrial genome proceeds, the entire disk becomes 
labelled. Evidence suggests that kDNA replication within individual infected host cells 
is not co-ordinated at any stage of the disease, or in any organ or tissue type (Figure 
4B, as example). Most infected cells contain both labelled and unlabelled amastigotes, 
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and it was also apparent from these TUNEL studies that amastigotes with replicating 
kDNA can co-exist in the same host cell as non-dividing trypomastigotes [26]. 
 
TUNEL staining of nuclear DNA was not detectable at any stage of parasite replication 
[26]. The replication status of the parasite genome during murine infections can 
however be assessed by EdU labelling [25, 26]. Following injection, this nucleoside 
analogue gets incorporated into the genome of any cell (both host and parasite) in 
which DNA is undergoing replication during the period of exposure, and is therefore a 
marker for cells transitioning through S-phase (Figure 5). Judging by the distribution 
of host cells with labelled nuclei, it can be inferred that EdU is widely available for 
uptake in mice tissue and that it is stably incorporated [26]. Studies with EdU revealed 
that replication of nuclear DNA is not synchronised within the parasite population of 
individual infected cells in vivo (Figure 5). Furthermore, as with TUNEL assays, 
infected host cells were observed that contained both replicating amastigotes and non-
replicating trypomastigotes [26]. This lack of developmental synchrony was observed 
in a wide range of organs and tissues, and during both the acute and chronic stages 
of the infection (Figure 5A and B). In line with this, imaging has revealed that the 
number of amastigotes within individual infected cells in vivo does not reflect a process 
that is tightly regulated; parasite numbers are predominantly random, and inconsistent 
with the type of geometrical progression that would be observed if replication was a 
co-ordinated event [26]. Recently, it has been reported that when T. cruzi intracellular 
amastigotes are exposed to EdU in vitro for 48 hours, there is a growth inhibitory effect 
[27]. However, this length of exposure is unlikely to be experienced in vivo following a 
single injection (Figure 5); with other thymidine analogues such as bromodeoxyuridine 
(BrdU), which is also used for DNA labelling experiments, the bioavailability is less 
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than 15 minutes [28]. Furthermore, in the experiments outlined above, which are 
based on end-point labelling, EdU incorporation is simply a marker for parasite DNA 
undergoing replication at the time of exposure. 
 
In addition to the canonical intracellular life-cycle stages of T. cruzi, the replicative 
amastigotes and the flagellated non-dividing trypomastigotes, other parasite forms 
have been reported in vitro [29-33]. However, these had not been observed in vivo, 
their roles during the infection process had not been established, and the possibility 
that they might represent culture artefacts not excluded. Using the imaging capabilities 
enabled by the bioluminescent:fluorescent reporter, several non-classical parasite 
forms have now been detected in mice during both chronic and acute stage infections 
[26]. Parasites, similar to the sphaeromastigote forms that have been observed in vitro 
[30], were visualised in a range of tissue types (Figure 6). These have an amastigote-
like morphology, and possess flagella of varying lengths. Their kinetoplasts are located 
in the anterior position that is characteristic of replicative forms and they exhibit a 
variable body length, which has no apparent link to the length of the protruding 
flagellum. Other types of flagellated parasites, with a morphology more typical of the 
non-infectious epimastigote forms found in the insect vector, have also been observed 
in vivo [26]. These epimastigote-like forms have an elongated cell body, with the 
kinetoplast arranged anterior to the nucleus. They have been shown to have wide 
tissue distribution in mice, and have even been found in the same infected cell as 




Taken together, these observations suggest that during infection, the T. cruzi life-cycle 
and its regulation are more complex than reported. It is implicit that replication and 
differentiation are not tightly regulated processes in which all parasites within an 
infected cell act in unison. Either specific trigger(s) of these developmental events are 
absent, or alternatively, not all parasites within the intracellular population have the 
capacity to respond. The identification of non-classical T. cruzi forms within infected 
mice further complicates our ability to understand the mechanisms that underpin 
parasite growth and differentiation. Whether these forms are developmental 
intermediates, or have a specific role in propagating the infection, remains unknown. 
However, their presence widely within the tissues of infected mice could have 
implications for the drug discovery process. It is unlikely that current high-throughput 
screening protocols fully capture the sensitivity, or otherwise, of these non-classical 
forms towards test compounds.  
 
Future prospects 
Why do parasites that are present in extremely low numbers during the chronic stage 
give rise to such severe pathology? Why are infections with T. cruzi generally life-long 
despite a vigorous adaptive immune response? Why are treatment failures such a 
common outcome of anti-parasitic therapy? Can we develop more effective and safer 
drugs? Progress in addressing these questions has been particularly hampered by 
difficulties in detecting and localising parasites during the chronic stage of infection. 
As outlined in this review, bioluminescence:fluorescence imaging methodology now 
enables the routine detection of infection foci in predictive experimental models, and 
provides scope for more detailed examination of the correlation between tissue 
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tropism and disease pathology. For example, it should now be feasible to visualise the 
immunological context of parasite infected cells at various stages of the disease, and 
in a range of tissues and organs, and to explore why parasites are able to avoid 
immune destruction and persist long-term in specific tissue niches. Similarly, it will be 
possible to reveal whether treatment failure is associated with an inability to kill 
parasites in particular tissue locations. The methodology will also be directly applicable 
to assessing if the recently postulated phenomenon of parasite dormancy [21] has a 
role in immune evasion and treatment failure. Chronic T. cruzi infection is no longer a 
black-box in which many crucial aspects of parasite biology critical to drug 
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Figure 1. Bioluminescence imaging of chronic murine T. cruzi infections. (A) In 
vivo imaging of BALB/c mice infected with T. cruzi (CL Brener strain) that express a 
red-shifted luciferase (ventral images). The number of days post-infection are 
indicated (left). Following the acute phase, the infection is controlled by the adaptive 
immune system, but not eradicated. The chronic stage is characterised by highly 
dynamic bioluminescent infection foci that vary on a day-to-day basis [11]. (B) Mice in 
the chronic stage of infection (day 106) were treated with 100 mg/kg benznidazole 
(once daily by the oral route) for 10 days and subjected to regular imaging. 
Bioluminescence was reduced to background levels by the end of treatment. To 
promote the outgrowth of any residual parasites, the mice were then 
immunosuppressed with cyclophosphamide (3 injections of 200 mg/kg i.p., 
administered at intervals of 3 days) (indicated by red arrow). None of the assessed 
mice relapsed. (C) Ex vivo imaging. Mice, chronically infected with bioluminescent T. 
cruzi, were perfused with d-luciferin in PBS via the heart immediately post-mortem. 
Organs and tissues were then excised, arrayed in Petri dishes as indicated (bottom 
right), and incubated in d-luciferin solution during bioluminescence evaluation [11]. 
Heat-maps are on log10 scales and indicate intensity of bioluminescence from low 
(blue) to high (red); the minimum and maximum radiances for the pseudo-colour scale 
are indicated.  
 
Figure 2. Detection of intracellular T. cruzi during chronic stage murine infection 
with parasites expressing a bioluminescent:fluorescent fusion protein. (A) An 
open reading frame containing linked red-shifted luciferase and mNeonGreen 
sequences was integrated into a ribosomal locus in T. cruzi CL Brener, with the 
hygromycin resistance gene (Hyg) as the selectable marker [22]. The expressed 
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fusion protein is both bioluminescent and fluorescent. The red-shifted luciferase (Luc 
PPyREh), linker sequence (blue), and mNeonGreen (mNEON) components are 
shown. The ribosomal promoter is indicated by a horizontal arrow. (B) Ex vivo imaging 
of a BALB/c mouse chronically infected (150 days) with parasites expressing the 
bioluminescent:fluorescent fusion protein. Organs and tissues were arranged as 
shown in the lower image. Bioluminescent foci can be excised and histological 
sections prepared [25]. (C) Images of a colon smooth muscle section obtained using 
the Zeiss LSM 510 confocal microscope. Red, neuron-specific -tubulin; Blue, DNA 
stained with DAPI; Green, fluorescent amastigotes.  
 
Figure 3. Fluorescence imaging of intracellular T. cruzi in multiple tissue sites 
during acute stage murine infection. (A) Confocal imaging of spleen and cardiac 
muscle sections obtained from BALB/c mice in the acute stage of infection (11 days). 
Red, DNA; Green, fluorescent amastigotes. (B) Oesophageal muscle section derived 
from a BALB/c mouse in the acute stage of infection (9 days), co-stained with 
antibodies specific to neuron-specific -tubulin (purple) and actin (red). Blue, DNA; 
Green, fluorescent amastigotes. (C) Colon section from a C3H mouse in the acute 
stage of infection (14 days) showing an infected smooth muscle cell. Blue, DNA; 
Green, fluorescent trypomastigotes. 
 
Figure 4. The use of TUNEL assays to explore the replicative status of 
intracellular T. cruzi in vivo. (A) Confocal imaging of parasites (CL Brener strain) in 
tissue sections derived from the colon of a C3H mouse in the acute stage of infection 
(day 14). Left, parasites indicated by green fluorescence. Right, image showing DNA 
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(DAPI) and TUNEL staining. Note the staining of antipodal sites on each side of the 
kDNA minicircle network, indicated by white arrows. Red staining on a green 
background appears as yellow. (B) Section of smooth muscle from the colon of a C3H 
mouse in the chronic stage of infection (day 213). Left, image showing DNA (DAPI 
staining), a single parasite nest (green fluorescence), and TUNEL staining. Note the 
TUNEL staining of genomic DNA in rapidly dividing gut mucosal cells (white arrow) 
and the kDNA staining in a minority of T. cruzi amastigotes. Right, expansion of a 
region of the parasite nest (in red circle), with DNA and TUNEL staining highlighting 
the asynchronous nature of kDNA replication in intracellular T. cruzi within an 
individual infected cell.  
 
Figure 5. The use of EdU labelling and confocal microscopy to explore the 
replicative status of intracellular T. cruzi in vivo. (A) Section of adipose tissue 
derived from a SCID mouse in the acute stage of infection (day 15) with T. cruzi CL 
Brener, showing parasites (green), DNA (blue) and EdU labelling. The mice were 
given a single injection with EdU, and sacrificed 16 hours later [26]. DAPI staining 
allows the large host cell nuclei (indicated by white arrow) to be discriminated from the 
smaller highly abundant parasite nuclei/kDNA. A minority of host cells were stained 
with EdU, indicating they were in S-phase during the period of exposure. Within 
individual infected host cells, parasite staining was intermittent, demonstrating that 
DNA replication is asynchronous within the population. (B) Sections of colon tissue 
taken from a C3H mouse during the chronic stage of infection (day 183) showing two 
infected smooth muscle cells. Asynchronous parasite DNA replication can be inferred 




Figure 6. Non-classical morphologies displayed by T. cruzi parasites during 
murine infections revealed by confocal imaging. (A) Section of smooth muscle 
derived from the rectum of a BALB/c mouse during acute stage infection (day 19) with 
T. cruzi CL Brener strain. Parasites, green; host cell DNA, red (parasite DNA appears 
as yellow, due to overlap with green fluorescence). (B) Cardiac tissue imaged 19 days 
post-infection. Some parasites have an amastigote-like morphology, and exhibit 
variable body and flagellum length, with the kinetoplasts located in an anterior position. 
Adapted from reference [26]. Bar = 5 μm. 
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